Clinical Trials Browser

NCT04479306 2026-04-16

Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer

Phase 1 Completed

37 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03648489 2024-09-20

DICE

Phase 2 Completed

134 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03154294 2024-07-26

Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors

Phase 1 Completed

19 enrolled 16 charts

Other solid neoplasm

Advanced Solid Tumor

NCT03097328 2024-04-29

Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma

Phase 2 Completed

39 enrolled 12 charts

Genitourinary

Carcinoma, Renal Cell

NCT02244463 2024-01-12

A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer

Phase 1/2 Completed

46 enrolled 18 charts

EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03017833 2023-10-04

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

Phase 1 Completed

31 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT03193853 2023-08-07

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

Phase 2 Completed

12 enrolled 11 charts

Breast

Triple Negative Breast Neoplasms

NCT02987959 2022-10-14

Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas

Phase 2 Terminated

6 enrolled 10 charts

Sarcoma

NCT02575339 2022-07-26

MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma

Phase 1/2 Terminated

11 enrolled 15 charts

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02719691 2022-07-25

Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer

Phase 1 Completed

47 enrolled 16 charts

Breast

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03430882 2022-06-21

Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors

Phase 1 Completed

35 enrolled

Other solid neoplasm

Recurrent Malignant Solid Neoplasm

NCT05022394 2022-05-27

Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study

Phase 1/2 Withdrawn

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT02988986 2021-09-22

ANETT

Phase 2 Completed

28 enrolled 9 charts

Breast

Breast Neoplasms

NCT02514824 2020-12-29

MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma

Phase 1/2 Completed

9 enrolled 10 charts

Dermatologic

Carcinoma, Merkel Cell

NCT02619669 2020-03-12

Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer

Phase 1 Withdrawn

Breast

Breast Neoplasms

NCT02727777 2020-03-12

Phase II Study of TAK228 in Relapsed Lymphoma

Phase 1/2 Terminated

4 enrolled 9 charts

Lymphoid

Lymphoma

NCT02091531 2019-11-21

Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients

Phase 2 Completed

9 enrolled 10 charts

Genitourinary

Metastatic Castration-Resistant Prostate Cancer

NCT03745911 2018-11-19

Paclitaxel and TAK-228 in Urothelial Carcinoma

Phase 2 Unknown

52 enrolled

Genitourinary

Carcinoma, Transitional Cell

NCT03205891 2018-01-17

Study of Brentuximab Vedotin Plus TAK228 for Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphomas

Phase 1 Withdrawn

Lymphoid

Lymphoma, Large-Cell, Anaplastic

NCT02812056 2017-03-27

Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies

Phase 1 Withdrawn

Other neoplasm

Malignant Neoplasms of Digestive Organs